Last reviewed · How we verify
Alginate oligosaccharide
Alginate oligosaccharide works by forming a protective barrier on the surface of the mucosa to treat conditions such as gastroesophageal reflux disease (GERD).
Alginate oligosaccharide works by forming a protective barrier on the surface of the mucosa to treat conditions such as gastroesophageal reflux disease (GERD). Used for Gastroesophageal reflux disease (GERD).
At a glance
| Generic name | Alginate oligosaccharide |
|---|---|
| Also known as | OligoG |
| Sponsor | AlgiPharma AS |
| Drug class | Gastrointestinal protectant |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 2 |
Mechanism of action
Alginate oligosaccharide forms a protective barrier on the surface of the mucosa, which helps to neutralize stomach acid and prevent damage to the esophagus. This can provide relief from symptoms of GERD, such as heartburn and regurgitation.
Approved indications
- Gastroesophageal reflux disease (GERD)
Common side effects
- Constipation
Key clinical trials
- Alginate vs Sucralfate for GERD Symptomatic Relief (PHASE2, PHASE3)
- Tolerance and Efficiency of an Intrabuccal Biological Film to Enhance Oral Dryness Sensation: The "PREDELFI" Clinical Pilot Study (NA)
- Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study. (PHASE4)
- A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis (PHASE2)
- A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain Treatment (PHASE4)
- A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection (PHASE2)
- A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (PHASE2)
- Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |